MoneyWorks4Me

The sales is pegged at Rs. 3383.70 millions for the September 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 4016.10 millions during the year-ago period.The Net Loss for the quarter ended September 2022 is Rs. -99.10 millions as compared to Net Profit of Rs. 302.30 millions of corresponding quarter ended September 2021Operating Profit reported a sharp decline to 312.90 millions from 756.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 3383.70 4016.10 -15.75 6684.40 8071.80 -17.19 12683.40 16168.80 -21.56
Other Income 37.70 35.10 7.41 102.50 93.10 10.10 187.60 284.10 -33.97
PBIDT 312.90 756.80 -58.65 474.50 1733.40 -72.63 991.10 4137.40 -76.05
Interest 219.60 170.70 28.65 444.60 359.90 23.53 752.70 844.70 -10.89
PBDT 93.30 585.30 -84.06 29.90 1366.90 -97.81 203.50 3292.70 -93.82
Depreciation 285.60 283.00 0.92 566.10 559.00 1.27 1120.10 1083.10 3.42
PBT -192.30 302.30 -163.61 -536.20 807.90 -166.37 -916.60 2209.60 -141.48
TAX -93.20 0.00 0.00 -245.30 0.00 0.00 -331.00 0.00 0.00
Deferred Tax -93.20 -59.30 57.17 -245.30 -147.70 66.08 -331.00 -386.40 -14.34
PAT -99.10 302.30 -132.78 -290.90 807.90 -136.01 -585.60 2209.60 -126.50
Equity 360.00 359.20 0.22 360.00 359.20 0.22 360.00 359.30 0.19
PBIDTM(%) 9.25 18.84 -50.93 7.10 21.47 -66.94 7.81 25.59 -69.46

Solara Active Pharma Share Price

511.05 -7.60 (-1.47%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: